A deal for Forxiga should be lined up as well. IMO.
27 Aug 2019: AstraZeneca has announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Forxiga (dapagliflozin).The designation is for the indication of delaying the progression of renal failure and prevent cardiovascular (CV) and renal death in patients with chronic kidney disease (CKD).
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
-0.015(4.92%) |
Mkt cap ! $47.42M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 31.0¢ | 28.5¢ | $191.2K | 643.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 56677 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.0¢ | 7590 | 2 |
View Market Depth
| Last trade - 15.36pm 26/06/2025 (20 minute delay) ? |
| PIQ (ASX) Chart |